DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Sacral Nerve Stimulation Market 2017-2021" report to their offering. The global sacral nerve stimulation market ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved expanded labeling for Medtronic’s InterStim II and InterStim Micro sacral neuromodulation ...

Background: Sacral nerve neuromodulation (SNM) therapy has been successfully applied in adult patients with urinary and fecal incontinence. Recently, SNM therapy showed good results in adults with ...

Former FierceMedTech Fierce 15 winner Axonics Modulation Technologies has received FDA approval for its rechargeable neuromodulation implant to treat bowel dysfunction. According to the company, its r ...

Medtronic (MDT) recently announced that it has received a favorable decision with respect to a long-standing patent dispute related to sacral neuromodulation. Specifically, per Medtronic’s press ...

Potential advantages of peroneal nerve stimulation include its noninvasiveness and relatively mild side effects. Peroneal electrical transcutaneous nerve modulation appears safe and tolerable for ...

The battery-free percutaneous sacral neuromodulation system has comparable efficacy to published rates for traditional sacral neuromodulation devices. The US Food and Drug Administration (FDA) has ...

Axonics Modulation Technologies (AXNX) intends to raise $100 million from the sale of its common stock in an IPO, per an amended registration statement. The company is developing a sacral ...